# Longterm Follow-up of Subjects Treated With bb2121

> **NCT02786511** · — · COMPLETED · sponsor: **Celgene** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Safety and efficacy assessments

## Key facts

- **NCT ID:** NCT02786511
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-28
- **Primary completion:** 2019-10-11
- **Final completion:** 2019-10-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786511, "Longterm Follow-up of Subjects Treated With bb2121". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02786511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*